Technical Analysis for AIM - AIM ImmunoTech Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 3.95% | |
| Earnings Movers | Other | 3.95% | |
| Lower Bollinger Band Touch | Weakness | 3.95% | |
| 20 DMA Resistance | Bearish | -5.73% | |
| Earnings Movers | Other | -5.73% | |
| 20 DMA Resistance | Bearish | -0.10% | |
| Fell Below 50 DMA | Bearish | -0.10% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 17 hours ago |
| Gap Up Partially Closed | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Down 1% | about 17 hours ago |
| Gapped Up (Partial) | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
AIM ImmunoTech Inc. Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Acid Infectious Diseases Health Care Melanoma Pancreatic Cancer Hepatitis B Carcinoma HIV Interferon Renal Cell Carcinoma Treatment Of Hepatitis Treatment Of Hepatitis B Chronic Fatigue Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.7487 |
| 52 Week Low | 0.3201 |
| Average Volume | 257,157 |
| 200-Day Moving Average | 0.48 |
| 50-Day Moving Average | 0.43 |
| 20-Day Moving Average | 0.42 |
| 10-Day Moving Average | 0.41 |
| Average True Range | 0.04 |
| RSI (14) | 44.44 |
| ADX | 23.2 |
| +DI | 11.84 |
| -DI | 22.23 |
| Chandelier Exit (Long, 3 ATRs) | 0.39 |
| Chandelier Exit (Short, 3 ATRs) | 0.49 |
| Upper Bollinger Bands | 0.46 |
| Lower Bollinger Band | 0.38 |
| Percent B (%b) | 0.28 |
| BandWidth | 20.94 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.44 | ||||
| Resistance 3 (R3) | 0.44 | 0.43 | 0.44 | ||
| Resistance 2 (R2) | 0.43 | 0.41 | 0.43 | 0.43 | |
| Resistance 1 (R1) | 0.41 | 0.41 | 0.40 | 0.41 | 0.43 |
| Pivot Point | 0.40 | 0.40 | 0.39 | 0.40 | 0.40 |
| Support 1 (S1) | 0.38 | 0.39 | 0.37 | 0.38 | 0.37 |
| Support 2 (S2) | 0.37 | 0.38 | 0.37 | 0.36 | |
| Support 3 (S3) | 0.35 | 0.37 | 0.36 | ||
| Support 4 (S4) | 0.35 |
